Get the Stockscreener App
8.155
1.68%
0.135
After Hours:
8.16
0.005
+0.06%
Evolus Inc stock is traded at $8.155, with a volume of 648.71K.
It is up +1.68% in the last 24 hours and up +30.06% over the past month.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
See More
Previous Close:
$8.02
Open:
$8.02
24h Volume:
648.71K
Relative Volume:
0.78
Market Cap:
$538.64M
Revenue:
$301.79M
Net Income/Loss:
$-43.42M
P/E Ratio:
-12.16
EPS:
-0.6705
Net Cash Flow:
$-44.87M
1W Performance:
+7.44%
1M Performance:
+30.06%
6M Performance:
+89.65%
1Y Performance:
+27.42%
1-Day Range:
$7.91
$8.258
1-Week Range:
$7.18
$8.43
52-Week Range:
$3.86
$8.43
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
8.155 | 536.33M | 301.79M | -43.42M | -44.87M | -0.6705 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
August 2026's Leading Growth Companies With Insider Confidence - Sahm
Midday Stock Roundup: Mobix Labs Shares Fall 21% at Midday - Orange County Business Journal
Renaissance Technologies LLC Lowers Stake in Evolus, Inc. $EOLS - marketbeat.com
Evolus, Inc. (EOLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS - marketbeat.com
Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evolus (NASDAQ:EOLS) Reaches New 1-Year HighHere's What Happened - MarketBeat
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade - Yahoo Finance
Evolus: The Injectable Platform Is Becoming The Real Moat (NASDAQ:EOLS) - Seeking Alpha
Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Trading Systems Reacting to (EOLS) Volatility - Stock Traders Daily
Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen - marketbeat.com
Needham Maintains Evolus(EOLS.US) With Hold Rating - moomoo.com
BTIG Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Evolus Inc (EOLS) Stock News Today - TradingKey
Evolus, Inc. (EOLS) Investor Outlook: Analyzing 97.93% Potential Upside in the Aesthetic Market - DirectorsTalk Interviews
Stifel Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Su - GuruFocus
Evolus, Inc. Q2 2026 Financial Results: Revenue, Risks, and Key Business Updates - Minichart
Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 21% and Adjusted EBITDA ... - Yahoo Finance
Earnings call transcript: Evolus tops revenue forecast in Q2 2026, shares rise - Investing.com South Africa
Evolus Q2 Earnings Call Highlights - MarketBeat
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2 - Yahoo Finance
Is Evolus Inc (EOLS) Undervalued After Q2 Earnings Beat? EPS: -0 - GuruFocus
Evolus Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Evolus Q2 2026 slides: profitability streak continues, guidance raised - Investing.com
Evolus, Inc. Q2 2026: Revenue $84.08M, EPS ($0.12) — 10-Q Summary - TradingView
Evolus (EOLS) Releases Q2 2026 Earnings: Revenue Growth and Narrower Losses - Quiver Quantitative
Evolus (Nasdaq: EOLS) posts higher sales and manages sizable debt load - stocktitan.net
Evolus Q2 revenue rises 21%, lifts 2026 outlook - TradingView
Evolus Q2 2026 Earnings: Revenue Rises 21% as Adjusted EBITDA Stays Positive - TradingKey
Evolus (NASDAQ: EOLS) lifts 2026 guidance after Q2 revenue hits $84.1 million - Stock Titan
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook - marketscreener.com
Evolus, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Evolus (NASDAQ:EOLS) Posts Earnings Results, Misses Expectations By $0.08 EPS - marketbeat.com
Evolus Deadline Alert - TMX Newsfile
Evolus Expands Symatese Partnership into Three New Markets - Orange County Business Journal
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme in Canada, Australia, and New Zealand - marketscreener.com
Evolus expands hyaluronic acid gel rights to three markets By Investing.com - Investing.com Nigeria
Evolus expands hyaluronic acid gel rights to three markets - Investing.com
Evolus, Inc. (NASDAQ: EOLS) extends Estyme deal to $500M markets - Stock Titan
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand - Yahoo Finance
Evolus Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Perceptive Advisors LLC Acquires New Stake in Evolus, Inc. $EOLS - marketbeat.com
Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.com
Evolus (EOLS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Evolus Inc (EOLS) Balance Sheet - TradingKey
Evolus Inc (EOLS) Income Statement - TradingKey
Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
EOLS|Evolus Inc|Price:5.980|Chg%:-0.010 - TradingKey
Evolus Inc (EOLS) Institutional Confidence - TradingKey
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
5.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):